Sector • Healthcare Industry • Laboratory Analytical Instruments |
Industry • Laboratory Analytical Instruments |
Sector • Healthcare |
A surge in revenue fueled to reduce the deficit, at PBIO amid the fiscal period closing Dec 31 2021
PBIO recorded fourth quarter of 2021 operating shortfall of $-1.221148 million
Published Apr 23 2022
CSIMarket Team / CSIMarket.com
On the contrary to Q3 Revenue Tumbled by -39.194 % from $0.52 million and EPS improved from $-0.82 per share.
In the fiscal span closing December 31 2021 Pressure Biosciences Inc reported net deficit of $-3.880 million, instead of deficit of $-4.265 million in the same reporting season a year ago.
Additionally, the Pressure Biosciences Inc pointed out as well net loss of $-16.08 million and for the fiscal year 2022, revenue of $1.73 million.
Biotechnology & Pharmaceuticals Pressure Biosciences Inc has decreased it's deficit per share to $-1.61 from $-3.42 in the prior fiscal year, while Revenue deteriorated by -13.63 % from $2.00 million a year prior.
Pressure Biosciences Inc is expected to report next financial results on May 17, 2023.
Other PBIO's news
Pressure Biosciences Inc Reports Mixed Financial Results for Q2 2023, with Modest Revenue Growth
Severe hit for the company over the most recent fiscal period
Losses Cut on Soft Sales at the PBIO during the second quarter of 2022 earnings season
Serious revenue slump, at the company all along the fiscal interval ending March 31 2022
A surge in revenue fueled to reduce the deficit, at PBIO amid the fiscal period closing Dec 31 2021
Other PBIO's news
Pressure Biosciences Inc Reports Mixed Financial Results for Q2 2023, with Modest Revenue Growth
Severe hit for the company over the most recent fiscal period
Losses Cut on Soft Sales at the PBIO during the second quarter of 2022 earnings season
Serious revenue slump, at the company all along the fiscal interval ending March 31 2022
A surge in revenue fueled to reduce the deficit, at PBIO amid the fiscal period closing Dec 31 2021